Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center (Q33397269)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center |
scientific article |
Statements
1 reference
Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center (English)
1 reference
Elie Azoulay
1 reference
Lionel Galicier
1 reference
Paul Coppo
1 reference
Alain Wynckel
1 reference
Antoine Froissart
1 reference
Marc Buffet
1 reference
Agnès Veyradier
1 reference
Pascale Poullin
1 reference
François Provôt
1 reference
Sandrine Malot
1 reference
Philippe Vanhille
1 reference
Jean-Paul Vernant
1 reference
Dominique Bordessoule
1 reference
Bertrand Guidet
1 reference
Eric Mariotte
1 reference
Eric Rondeau
1 reference
Karine Clabault
1 reference
Gabriel Choukroun
1 reference
Claire Presne
1 reference
Jacques Pourrat
1 reference
Mohamed Hamidou
1 reference
French Thrombotic Microangiopathies Reference Center
1 reference
1 January 2012
1 reference
1 reference
Identifiers
1 reference